Antirotinib Hydrochloride Plus Whole Brain Radiotherapy for Small Cell Lung Cancer With Brain Metastases

This was a single-center, single-arm trail. Enrolled patients were pathologically diagnosed with small cell lung cancer and had completed at least 4 cycles of first-line chemotherapy. Patients with brain metastases at first visit or during treatment were treated with whole brain radiotherapy combined with anlotinib hydrochloride. Oral antirotinib was started 2 weeks before radiotherapy for brain metastases and stopped for 1 week after 2 weeks. After radiotherapy, antirotinib was continued until tumor progression. Efficacy and toxicity data were collected for evaluation and analysis.

Inclusion criteria

• Small cell lung cancer confirmed by pathology, completion of at least 4 cycles of first-line chemotherapy, and measurable disease according to RECIST criteria.
• The expected survival time is more than 3 months.
• Intracranial metastases ≤10.
• Adequate organ and bone marrow function.

Exclusion criteria

• Patients who have used antiangiogenic drugs within the previous 1 month.
• Non-small cell lung cancer (including small cell carcinoma and non-small cell carcinoma mixed lung cancer).
• Small cell lung cancer with hilar invasion or hemoptysis.
• Patients with intracranial acute, subacute cerebral infarction, intracranial lesions acute, subacute hemorrhage.
• An unresolved acute toxic reaction period higher than grade 2 of CTC-AE(4.0) due to any prior treatment.
• Advanced patients with severe symptoms, tumors that have spread to the internal organs, and a short-term risk of life-threatening complications.
• Patients with life-threatening conditions of other severe and/or uncontrolled diseases.